Halozyme Therapeutics, Inc. (HALO)
$
73.15
+0.34 (0.46%)
Key metrics
Financial statements
Free cash flow per share
4.4559
Market cap
8.5 Billion
Price to sales ratio
7.2253
Debt to equity
4.5353
Current ratio
8.3606
Income quality
0.9829
Average inventory
173.2 Million
ROE
1.3663
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally, focusing on advancing drug delivery technologies. The company recorded an operating income of $551,475,000.00 reflecting its earnings from core operations, while incurring an interest expense of $18,095,000.00 indicative of its debt servicing obligations. The total costs and expenses for the company are $463,849,000.00 highlighting its overall spending. Additionally, the diluted EPS is $3.43 accounting for potential share dilution, and the company incurred an income tax expense of $113,041,000.00 indicating its tax obligations. Its flagship product, Hylenex recombinant, utilizes patented recombinant human hyaluronidase enzyme (rHuPH20) to facilitate subcutaneous fluid administration, enhancing the dispersion and absorption of other injected drugs. The company develops several important therapeutics including Perjeta, RITUXAN HYCELA, and MabThera SC for non-Hodgkin lymphoma, as well as HYQVIA for immunodeficiency disorders. Furthermore, collaborations with several renowned organizations support its innovative efforts in treating various conditions. The stock is affordable at $57.65 suitable for budget-conscious investors, which, combined with a high average trading volume of 2,167,693.00 indicates strong liquidity. With a mid-range market capitalization of $8,556,062,900.00 the company is a steady performer in the competitive landscape of the Biotechnology industry. As a key player in this sector, it significantly contributes to the overall market landscape, driving innovation and growth. In addition to its successful products, the company is actively developing treatments such as Tecentriq for non-small cell lung cancer and OCREVUS for multiple sclerosis, alongside other promising therapies aimed at a variety of serious health conditions. Halozyme's extensive collaborations with top pharmaceutical companies also underscore its commitment to addressing unmet medical needs and advancing healthcare outcomes globally.
Is Halozyme Therapeutics, Inc. (HALO) a good investment?
Investing in Halozyme Therapeutics, Inc. (HALO) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B+, with a Bullish outlook. Always conduct your own research before investing.
What is Halozyme Therapeutics, Inc. (HALO)'s stock forecast?
Analysts predict Halozyme Therapeutics, Inc. stock to fluctuate between $42.01 (low) and $74.07 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Halozyme Therapeutics, Inc.'s market capitalization?
As of 2025-08-29, Halozyme Therapeutics, Inc.'s market cap is $8,556,062,900, based on 116,966,000 outstanding shares.
How does Halozyme Therapeutics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Halozyme Therapeutics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Halozyme Therapeutics, Inc. (HALO) stock?
To buy Halozyme Therapeutics, Inc. (HALO) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for HALO. Place an order (Market, Limit, etc.).
What is the best time to invest in Halozyme Therapeutics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Halozyme Therapeutics, Inc. perform in the last earnings report?
Revenue: $1,015,324,000 | EPS: $3.50 | Growth: 64.32%.
Where can I find Halozyme Therapeutics, Inc.'s investor relations reports?
Visit https://www.halozyme.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Halozyme Therapeutics, Inc.?
You can explore historical data from here
What is the all-time high and low for Halozyme Therapeutics, Inc. stock?
All-time high: $74.07 (2025-08-27) | All-time low: $29.85 (2023-05-09).
What are the key trends affecting Halozyme Therapeutics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
fxempire.com
Halozyme Therapeutics, Inc. (HALO) shares up 491% since first Big Money outlier inflow signal in March 2014.
prnewswire.com
SAN DIEGO , Aug. 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Investor Relations and Corporate Communications, are scheduled to participate and host investor meetings at the following investor conferences. Details on the Company's participation are as follows: Event: 2025 Wells Fargo Healthcare Conference Format: Fireside Chat and 1x1 Meetings Presentation Date: Thursday, September 4, 2025 Presentation Time: 10:30am PT / 1:30pm ET Location: Boston, MA Event: Morgan Stanley 23rd Annual Global Healthcare Conference Format: Fireside Chat and 1x1 Meetings Date: Monday, September 8, 2025 Presentation Time: 4:45am PT / 7:45am ET Location: New York, NY Event: H.C.
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
zacks.com
Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.
seekingalpha.com
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Helen I. Torley - President, CEO & Director Nicole LaBrosse - Senior VP & CFO Tram Bui - Head of Investor Relations & Corporate Communications Conference Call Participants Adam Ferrari - JPMorgan Chase & Co, Research Division Brendan Mychal Smith - TD Cowen, Research Division Corinne Johnson - Goldman Sachs Group, Inc., Research Division Jason Nicholas Butler - Citizens JMP Securities, LLC, Research Division Michael Gennaro DiFiore - Evercore ISI Institutional Equities, Research Division Mitchell Swaroop Kapoor - H.C.
zacks.com
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
prnewswire.com
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma SAN DIEGO , July 23, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval of a new indication for DARZALEX Faspro® (daratumumab) co-formulated with ENHANZE®, as monotherapy for the treatment of adult patients with smouldering multiple myeloma (SMM) at high-risk of developing multiple myeloma. "This approval reinforces DARZALEX Faspro with ENHANZE as a foundational treatment across all stages of multiple myeloma," said Dr. Helen Torley, President and CEO of Halozyme.
See all news
